Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences

Overview

Journal Sci Rep

Specialty Science

Date 2020 Jun 4

PMID 32488071

Citations 3

Authors

Brian S Gerstenberger

Mary Ellen Banker

James D Clark

Martin E Dowty

Andrew Fensome

Roger Gifford

Matthew C Griffor

Martin Hegen

Brett D Hollingshead

John D Knafels

Tsung H Lin

James F Smith

Felix F Vajdos

Affiliations

Soon will be listed here.

Abstract

Translation of modulation of drug target activity to therapeutic effect is a critical aspect for all drug discovery programs. In this work we describe the profiling of a non-receptor tyrosine-protein kinase (TYK2) inhibitor which shows a functionally relevant potency shift between human and preclinical species (e.g. murine, dog, macaque) in both biochemical and cellular assays. Comparison of the structure and sequence homology of TYK2 between human and preclinical species within the ATP binding site highlights a single amino acid (I960 → V) responsible for the potency shift. Through TYK2 kinase domain mutants and a TYK2 980I knock-in mouse model, we demonstrate that this single amino acid change drives a functionally relevant potency difference that exists between human and all evaluated preclinical species, for a series of TYK2 inhibitors which target the ATP binding site.

Citing Articles

Data science in drug discovery safety: Challenges and opportunities.

Coltman N, Roberts R, Sidaway J Exp Biol Med (Maywood). 2023; 248(21):1993-2000.

PMID: 38062553 PMC: 10798188. DOI: 10.1177/15353702231215890.

From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases.

Hromadova D, Elewaut D, Inman R, Strobl B, Gracey E Front Genet. 2021; 12:685280.

PMID: 34290741 PMC: 8287328. DOI: 10.3389/fgene.2021.685280.

Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Liu J, Ting J, Al-Azzam S, Ding Y, Afshar S Int J Mol Sci. 2021; 22(6).

PMID: 33802091 PMC: 8001105. DOI: 10.3390/ijms22062805.

References

Webb D . Animal models of human disease: inflammation. Biochem Pharmacol. 2013; 87(1):121-30. DOI: 10.1016/j.bcp.2013.06.014. View

Kruger F, Overington J . Global analysis of small molecule binding to related protein targets. PLoS Comput Biol. 2012; 8(1):e1002333. PMC: 3257267. DOI: 10.1371/journal.pcbi.1002333. View

OShea J, Gadina M . Selective Janus kinase inhibitors come of age. Nat Rev Rheumatol. 2019; 15(2):74-75. DOI: 10.1038/s41584-018-0155-9. View

Shachar I, Karin N . The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol. 2012; 93(1):51-61. DOI: 10.1189/jlb.0612293. View

Schwartz D, Kanno Y, Villarino A, Ward M, Gadina M, OShea J . JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017; 16(12):843-862. DOI: 10.1038/nrd.2017.201. View

Min X, Ungureanu D, Maxwell S, Hammaren H, Thibault S, Hillert E . Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2). J Biol Chem. 2015; 290(45):27261-27270. PMC: 4646372. DOI: 10.1074/jbc.M115.672048. View

Dendrou C, Cortes A, Shipman L, Evans H, Attfield K, Jostins L . Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016; 8(363):363ra149. PMC: 5737835. DOI: 10.1126/scitranslmed.aag1974. View

Flanagan M, Blumenkopf T, Brissette W, Brown M, Casavant J, Shang-Poa C . Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010; 53(24):8468-84. DOI: 10.1021/jm1004286. View

He X, Chen X, Zhang H, Xie T, Ye X . Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018). Expert Opin Ther Pat. 2019; 29(2):137-149. DOI: 10.1080/13543776.2019.1567713. View

10.

Rosenblum J, Nomanbhoy T, Kozarich J . Functional interrogation of kinases and other nucleotide-binding proteins. FEBS Lett. 2013; 587(13):1870-7. DOI: 10.1016/j.febslet.2013.05.008. View

11.

Fensome A, Ambler C, Arnold E, Banker M, Brown M, Chrencik J . Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018; 61(19):8597-8612. DOI: 10.1021/acs.jmedchem.8b00917. View

12.

Clark J, Flanagan M, Telliez J . Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014; 57(12):5023-38. DOI: 10.1021/jm401490p. View

13.

Argiriadi M, Goedken E, Banach D, Borhani D, Burchat A, Dixon R . Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Struct Biol. 2012; 12:22. PMC: 3478977. DOI: 10.1186/1472-6807-12-22. View

14.

Bissantz C, Kuhn B, Stahl M . A medicinal chemist's guide to molecular interactions. J Med Chem. 2010; 53(14):5061-84. PMC: 2905122. DOI: 10.1021/jm100112j. View

15.

Chrencik J, Patny A, Leung I, Korniski B, Emmons T, Hall T . Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol. 2010; 400(3):413-33. DOI: 10.1016/j.jmb.2010.05.020. View

16.

Rudolf A, Skovgaard T, Knapp S, Jensen L, Berthelsen J . A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination. PLoS One. 2014; 9(6):e98800. PMC: 4051630. DOI: 10.1371/journal.pone.0098800. View

17.

Singh M, Murriel C, Johnson L . Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. Cancer Res. 2012; 72(11):2695-700. DOI: 10.1158/0008-5472.CAN-11-2786. View

18.

Chaix J, Tessmer M, Hoebe K, Fuseri N, Ryffel B, Dalod M . Cutting edge: Priming of NK cells by IL-18. J Immunol. 2008; 181(3):1627-31. PMC: 5154249. DOI: 10.4049/jimmunol.181.3.1627. View

19.

Liang J, Van Abbema A, Balazs M, Barrett K, Berezhkovsky L, Blair W . Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem. 2013; 56(11):4521-36. DOI: 10.1021/jm400266t. View

20.

Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H . IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998; 161(7):3400-7. View